A 006
Alternative Names: A-006 - MeiraGTxLatest Information Update: 24 Apr 2023
At a glance
- Originator MeiraGTx
- Class Antibodies; Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Wet age-related macular degeneration